MedTrace Logo

The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers

NCT00612079 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-09-17

No results posted yet for this study

Summary

This study aims to further validate and extend our previous findings insofar that the effect of the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole on sensorimotor gating processes and its relationship to cognitive performance shall be explored.

Conditions

  • Healthy

Interventions

DRUG

Sertindole

oral 3 x 4mg

DRUG

Placebo

3 x 4mg Placebo

Sponsors & Collaborators

  • Psychiatric University Hospital, Zurich

    collaborator OTHER

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Franz X. Vollenweider, Prof. Dr. med. · University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612079 on ClinicalTrials.gov